Philips announced that the first U.S. patient has been enrolled in the investigational device exemption trial of its drug-coated balloon designed to treat below-the-knee lesions.
The trial, ILLUMENATE BTK, will compare the DCB (Stellarex 0.014) to percutaneous transluminal angioplasty in patients with critical limb ischemia, according to a press release issued by the company.
This activity is supported by educational funding provided by Amarin Pharma Inc., Amgen, and Quest Diagnostics.
American Heart Association Scientific Sessions
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.